Share-based Payment Arrangement, Expense in USD of Kezar Life Sciences, Inc. from 2016 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Kezar Life Sciences, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and change rate from 2016 to Q3 2025.
  • Kezar Life Sciences, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $2,136,000.000, a 32.9% decline year-over-year.
  • Kezar Life Sciences, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $10,643,000.000, a 17.6% decline year-over-year.
  • Kezar Life Sciences, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $13,011,000.000, a 28.3% decline from 2023.
  • Kezar Life Sciences, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $18,137,000.000, a 29.5% increase from 2022.
  • Kezar Life Sciences, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $14,006,000.000, a 84.4% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Kezar Life Sciences, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $10,643,000 $2,136,000 -$1,049,000 -32.9% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025
Q2 2025 $11,692,000 $2,421,000 -$664,000 -21.5% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025
Q1 2025 $12,356,000 $2,779,000 -$655,000 -19.1% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025
Q4 2024 $13,011,000 $3,307,000 +$87,000 +2.7% 01 Oct 2024 31 Dec 2024 10-K 25 Mar 2025
Q3 2024 $12,924,000 $3,185,000 -$3,449,000 -52% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025
Q2 2024 $16,373,000 $3,085,000 -$935,000 -23.3% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025
Q1 2024 $17,308,000 $3,434,000 -$829,000 -19.4% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025
Q4 2023 $18,137,000 $3,220,000 -$597,000 -15.6% 01 Oct 2023 31 Dec 2023 10-K 25 Mar 2025
Q3 2023 $18,734,000 $6,634,000 +$2,847,000 +75.2% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024
Q2 2023 $15,887,000 $4,020,000 +$722,000 +21.9% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024
Q1 2023 $15,165,000 $4,263,000 +$1,159,000 +37.3% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024
Q4 2022 $14,006,000 $3,817,000 +$1,964,000 +1.1% 01 Oct 2022 31 Dec 2022 10-K 25 Mar 2025
Q3 2022 $12,042,000 $3,787,000 +$1,909,000 +1% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023
Q2 2022 $10,133,000 $3,298,000 +$1,361,000 +70.3% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023
Q1 2022 $8,772,000 $3,104,000 +$1,176,000 +61% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023
Q4 2021 $7,596,000 $1,853,000 +$573,000 +44.8% 01 Oct 2021 31 Dec 2021 10-K 14 Mar 2024
Q3 2021 $7,023,000 $1,878,000 +$607,000 +47.8% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022
Q2 2021 $6,416,000 $1,937,000 +$718,000 +58.9% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022
Q1 2021 $5,698,000 $1,928,000 +$755,000 +64.4% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022
Q4 2020 $4,943,000 $1,280,000 +$273,000 +27.1% 01 Oct 2020 31 Dec 2020 10-K 14 Mar 2023
Q3 2020 $4,670,000 $1,271,000 +$181,000 +16.6% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021
Q2 2020 $4,489,000 $1,219,000 +$210,000 +20.8% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021
Q1 2020 $4,279,000 $1,173,000 +$272,000 +30.2% 01 Jan 2020 31 Mar 2020 10-Q 12 May 2021
Q4 2019 $4,007,000 $1,007,000 +$558,000 +1.2% 01 Oct 2019 31 Dec 2019 10-K 17 Mar 2022
Q3 2019 $3,449,000 $1,090,000 +$660,000 +1.5% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020
Q2 2019 $2,789,000 $1,009,000 +$21,000 +2.1% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020
Q1 2019 $2,768,000 $901,000 +$775,000 +6.2% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020
Q4 2018 $1,993,000 $449,000 01 Oct 2018 31 Dec 2018 10-K 11 Mar 2021
Q3 2018 $430,000 +$394,000 +10.9% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019
Q2 2018 $988,000 +$950,000 +25% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019
Q1 2018 $126,000 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019
Q3 2017 $36,000 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018
Q2 2017 $38,000 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018

Kezar Life Sciences, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $13,011,000 -$5,126,000 -28.3% 01 Jan 2024 31 Dec 2024 10-K 25 Mar 2025
2023 $18,137,000 +$4,131,000 +29.5% 01 Jan 2023 31 Dec 2023 10-K 25 Mar 2025
2022 $14,006,000 +$6,410,000 +84.4% 01 Jan 2022 31 Dec 2022 10-K 25 Mar 2025
2021 $7,596,000 +$2,653,000 +53.7% 01 Jan 2021 31 Dec 2021 10-K 14 Mar 2024
2020 $4,943,000 +$936,000 +23.4% 01 Jan 2020 31 Dec 2020 10-K 14 Mar 2023
2019 $4,007,000 +$2,014,000 +1% 01 Jan 2019 31 Dec 2019 10-K 17 Mar 2022
2018 $1,993,000 +$1,790,000 +8.8% 01 Jan 2018 31 Dec 2018 10-K 11 Mar 2021
2017 $203,000 +$75,000 +58.6% 01 Jan 2017 31 Dec 2017 10-K 12 Mar 2020
2016 $128,000 01 Jan 2016 31 Dec 2016 10-K 26 Mar 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.